- Home
- VNO vs CORT Comparison
VNO vs CORT Comparison
Compare VNO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- CORT
- Stock Information
- Founded
- VNO 1946
- CORT 1998
- Country
- VNO United States
- CORT United States
- Employees
- VNO N/A
- CORT N/A
- Industry
- VNO Real Estate Investment Trusts
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- CORT Health Care
- Exchange
- VNO Nasdaq
- CORT Nasdaq
- Market Cap
- VNO 7.0B
- CORT 7.5B
- IPO Year
- VNO N/A
- CORT N/A
- Fundamental
- Price
- VNO $37.87
- CORT $68.52
- Analyst Decision
- VNO Hold
- CORT Strong Buy
- Analyst Count
- VNO 11
- CORT 4
- Target Price
- VNO $37.91
- CORT $142.00
- AVG Volume (30 Days)
- VNO 1.9M
- CORT 1.6M
- Earning Date
- VNO 08-04-2025
- CORT 07-28-2025
- Dividend Yield
- VNO 1.96%
- CORT N/A
- EPS Growth
- VNO 248.25
- CORT 8.36
- EPS
- VNO 0.52
- CORT 1.14
- Revenue
- VNO $1,929,890,000.00
- CORT $685,446,000.00
- Revenue This Year
- VNO N/A
- CORT $35.83
- Revenue Next Year
- VNO $4.97
- CORT $35.24
- P/E Ratio
- VNO $72.03
- CORT $59.62
- Revenue Growth
- VNO 2.98
- CORT 30.93
- 52 Week Low
- VNO $25.87
- CORT $29.42
- 52 Week High
- VNO $46.63
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- VNO 45.53
- CORT 44.85
- Support Level
- VNO $36.95
- CORT $66.49
- Resistance Level
- VNO $39.28
- CORT $72.72
- Average True Range (ATR)
- VNO 1.14
- CORT 2.79
- MACD
- VNO -0.19
- CORT -0.49
- Stochastic Oscillator
- VNO 39.05
- CORT 26.81
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.